Signs of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Hydrocodone | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dexbrompheniramine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Mirtazapine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Orphenadrine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Pramipexole | Dexbrompheniramine may increase the sedative activities of Pramipexole. |
| Ropinirole | Dexbrompheniramine may increase the sedative activities of Ropinirole. |
| Rotigotine | Dexbrompheniramine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine. |
| Sodium oxybate | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Thalidomide | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Dexbrompheniramine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine. |
| Ethanol | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alaproclate. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Citalopram. |
| Escitalopram | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram. |
| Amphetamine | Amphetamine may decrease the sedative activities of Dexbrompheniramine. |
| Phentermine | Phentermine may decrease the sedative activities of Dexbrompheniramine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Dexbrompheniramine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Dexbrompheniramine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Dexbrompheniramine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Dexbrompheniramine. |
| MMDA | MMDA may decrease the sedative activities of Dexbrompheniramine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Dexbrompheniramine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexbrompheniramine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexbrompheniramine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Dexbrompheniramine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Dexbrompheniramine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Dexbrompheniramine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Dexbrompheniramine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Dexbrompheniramine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Dexbrompheniramine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Dexbrompheniramine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Dexbrompheniramine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Dexbrompheniramine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Dexbrompheniramine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexbrompheniramine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Dexbrompheniramine. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dexbrompheniramine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Dexbrompheniramine. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dexbrompheniramine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Cyproheptadine. |
| Imipramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Imipramine. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Nortriptyline. |
| Amoxapine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Amoxapine. |
| Nicardipine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nicardipine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Propiomazine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Maprotiline. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tolterodine. |
| Doxepin | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Doxepin. |
| Desipramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Desipramine. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Solifenacin. |
| Pizotifen | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Pizotifen. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Trimebutine. |
| Dosulepin | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Dosulepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zopiclone. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Azithromycin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ranolazine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulfisoxazole. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Diltiazem. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nimodipine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dexbrompheniramine. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ciprofloxacin. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fluorouracil. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Perflutren. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cinnarizine. |
| Atropine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Atropine. |